Passage Bio, the Philadelphia-based neurodegenerative genetic medicines company is planning to lay off about 55% of its staff as it pivots from an in-house to outsourced analytical testing model.
https://www.fiercebiotech.com/biotech/igm-y-mabs-passage-bio-and-more-telegraph-staff-cuts-amid-pipeline-and-business-structure